Table 2.
Comparison of patient’s background and pathological outcomes
| Variables | All Patients (n = 253) | GGH expression | P value | FPGS expression | P value | ||
|---|---|---|---|---|---|---|---|
| High group (n = 211) | Low group (n = 42) | High group (n = 222) | Low group (n = 31) | ||||
| Age (years), median (range) | 65 (38–98) | 70 (48–98) | 64 (38–87) | < 0.001 | 68 (44–89) | 69 (380–98) | 0.46 |
| Gender | 0.94 | 0.25 | |||||
| Male | 170 (67.2%) | 142 (67.3%) | 28 66.7%) | 152 (68.5%) | 18 (58.1%) | ||
| Female | 83 (32.8%) | 69 (32.7%) | 14 (33.3%) | 70 (31.5%) | 13 41.9%) | ||
| Histological type | 0.012 | 0.66 | |||||
| Undifferentiated | 140 (55.3%) | 108 (51.2%) | 32 76.2%) | 124 (55.9%) | 16 (51.6%) | ||
| Differentiated | 112 (44.3%) | 102 48.3%) | 10 (23.8%) | 98 (44.1%) | 15 (48.4%) | ||
| Tumor size (mm) | 0.12 | 0.84 | |||||
| < 65 | 135 (53.4%) | 108 (51.2%) | 27 (64.3%) | 119 (53.6%) | 16 (51.6%) | ||
| 65 ≤ | 118 (46.6%) | 103 (48.8%) | 15 (35.7%) | 103 (46.4%) | 15 (48.4%) | ||
| Pathological T factor | 0.80 | 0.32 | |||||
| T1–3 | 119 (47.0%) | 100 47.4%) | 19 (45.2%) | 107 (48.2%) | 12 (38.7%) | ||
| T4 | 134 (53.0%) | 111 (52.6%) | 23 (54.8%) | 115 (51.8%) | 19 (61.3%) | ||
| Pathological N factor | 0.60 | 0.69 | |||||
| N0 | 56 (22.1%) | 48 (22.75%) | 8 (19.1%) | 50 (22.5%) | 6 (19.4%) | ||
| N1–3 | 197 (77.9%) | 163 (77.3%) | 34 (81.0%) | 172 (77.5%) | 25 (80.6%) | ||
| Stage | 0.71 | 0.59 | |||||
| II | 103 (49.7%) | 87 (41.2%) | 16 (38.1%) | 89 (40.1%) | 14 (45.2%) | ||
| III | 150 (59.3%) | 124 (58.8%) | 26 (61.9%) | 133 (59.9%) | 17 (54.8%) | ||
| Vascular invasion | 0.028 | 0.086 | |||||
| v0 | 73 (28.9%) | 55 (26.1%) | 18 (42.9%) | 60 (27.0%) | 13 (41.9%) | ||
| v1–3 | 180 (71.1%) | 156 (73.9%) | 24 (57.1%) | 162 (73.0%) | 18 (58.1%) | ||
| Lymphatic invasion | 0.87 | 0.094 | |||||
| ly0 | 81 (32.0%) | 68 (32.2%) | 13 (31.0%) | 67 (30.2%) | 14 (45.2%) | ||
| ly1–3 | 172 (68.0%) | 143 (67.8%) | 29 (69.0%) | 155 (69.8%) | 17 (54.8%) | ||
| Adjuvant therapy | 0.35 | 0.46 | |||||
| Yes | 146 (42.3%) | 119 (56.4%) | 27 (64.3%) | 130 (58.6%) | 16 (51.6%) | ||
| No | 107 (57.7%) | 92 (43.6%) | 15 (35.7%) | 92 (41.4%) | 15 (48.4%) | ||